echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Digestive System Information > JCC: Which ulcerative colitis patients can benefit from fecal transplantation?

    JCC: Which ulcerative colitis patients can benefit from fecal transplantation?

    • Last Update: 2020-09-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Fecal transplantation (FMT) may sound incredible, but the use of feces has long been a hot area of research in the medical community.
    as the name suggests, a fecal transplant is the delivery of one person's stool through the intestines to another.
    aims to transplant beneficial microorganisms from a healthy person's intestines into a problem recipient and to treat the disease.
    don't look down on the process, it has the risk of saving some people's lives.
    fecal microbiome transplantation (FMT) has been shown to be effective in inducing remission in patients with active ulcerative colitis (UC).
    there is no consensus on what factors affect the effectiveness of FMT, so this study aims to do the same.
    researchers treated patients with ulcerative colitis who performed fecal transplants with FMT through colonoscopy at weeks 0, 2, 6, 10, 14, 18 and 22.
    response to FMT is defined as clinical remission of corticosteroid-free at the 30th week.
    results showed that out of 140 active UC patients treated with FMT, a total of 93 patients completed the multi-stage FMT program (average age 34.96 to 11.27 years old, 62.36 percent for men, and an average score of 8.07 to 2.00) at the Mayo Clinic.
    57 patients (61.29%) achieved clinical remission.
    age (OR 0.93, 95% CI: 0.89-0.97, p-0.001), moderate (Mayo clinical score 6-9), disease severity (OR 3.01,95% CI 1.1 2 to 8.06, p s 0.025) and endoscope Mayo score 2 (OR 5.55, 95% CI 2.18-14.06, p slt;0.001) are indicators of significant predictive mitigation in a single-factor analysis.
    age, disease level E2 and endoscope Mayo score 2 (OR 0.925, 95% CI 0.88-0.97, p s 0.002; OR 2.89,95%CI 1.01-8.25, p s 0.04 and OR 8.43, 95% CI 2.38-29.84, p s 0.001) were associated with clinical regression of multi-factor logistic regression, respectively.
    younger age, disease level e2 and endoscope Mayo score 2 were effective predictive factors for FMT clinical remission in active UC patients.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.